Tango

A phase 2 clinical trial for people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease

Status
Start Date
Condition
Estimated
enrollment
Age Range
Phase
Study Type

Objective

To learn if an investigational drug (BIIB092) is a safe and potentially effective treatment for people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease.

The investigational drug

BIIB092 is designed to target tau – a protein that builds up in the brains of people with Alzheimer’s disease (known as tau tangles). The trial will ask if taking BIIB092 early in the disease’s progression can reduce the spread of tau in the brain and if it may potentially slow the progress of the disease.

Key eligibility criteria

  • Men and women
  • 50-80 years old
  • Diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
  • Undiagnosed but experiencing frequent memory problems beyond normal aging
  • Otherwise healthy with no other significant/uncontrolled medical issues
  • Have a study partner who can attend certain appointments and provide information about the study participant’s health

Trial length

  • Approximately 3 years 2 months
  • Optional potential long-term extension study